BAG Health Care would like to introduce a new product of the ERY SPOT® product line, the ERY SPOT® Weak D-TYPE kit. The kit is CE-certified acc. to IVDD, att. II, list A (for patient typing) and will be available in January 2018.

Rhesus (Rh) is the 2nd most important blood group system after ABO and consists of more than 200 alleles. The red blood cell surface of an individual may or may not carry an immunogenic D antigen (D antigen present = RhD positive or D antigen absent = RhD negative). Rhesus antigens are very immunogenic: RHD 70% > c > E > C: 0,2%*. That means that Rhesus D has the highest immunogenicity!

Specific antibodies against Rhesus antigens are involved in acute and severe hemolytic transfusion reactions (HTR) as well as hemolytic disease of the fetus and newborn.

A clear serological detection of Rh weak D is very difficult, because there are many weak D variants reacting differently. Molecular genetic typing is the only safe way to define the RH Weak D allele. This complex situation has been taken into account when the German transfusion guidelines were changed in 2017 and weak D molecular genetic typing became mandatory.

The ERY SPOT® Weak D-TYPE kit is designed to resolve serologically weak D typed samples or samples with unclear Rh D status. The kit types more than 25 different Weak D alleles and also identifies, if the Rhesus D antigen is present or not (RhD positive/negative).

In case of decision for Rh D positive/negative transfusion it helps you differentiate between the most important RHD* weak D type 1 -4 and all other variants.

For more information about our ERY SPOT® products please follow the link.

* Kretschmer et al. Transfusionsmedizin-Klinische Hämotherapie. Thieme Verlag, 2008

In which language should this page be displayed in the future?

In welcher Sprache soll diese Seite in Zukunft bevorzugt angezeigt werden?

de gb